Laura Mauri, M.D., M.Sc., is the Senior Vice President, Chief Scientific, Medical, and Regulatory Officer at Medtronic. In this role, Laura leads the global company’s scientific, medical, clinical research and regulatory affairs functions and is a member of the Medtronic Executive Committee. Her strategic responsibilities include driving the integration of medical and scientific intelligence to inform business decisions and delivering a transformative approach to patient safety and patient engagement.
Laura formally established an independent, enterprise-wide Medical Safety function in 2022 to further advance a patient-centered approach to healthcare technology innovation at every stage of the product lifecycle. In addition, she has led the effort to connect and align the chief medical officers across Medtronic’s businesses to create a community of medical experts collaborating to provide insights and input into strategic decision-making and technology investments. She sits on the company’s Capital Allocation Committee to ensure the company has a clear appraisal of the medical and scientific landscape when making investment decisions, helping deliver effective and reliable innovations for patients and healthcare providers.
Laura joined Medtronic in September of 2018, in the role of Vice President of Global Clinical Research and Analytics. Laura was the executive sponsor of the company’s efforts to bring together Medtronic’s global clinical research leaders across all product areas and led the company’s clinical trial response and mitigation plans for COVID-19. She has also been responsible for leading the development of novel analytical and data science solutions to provide global clinical evidence for Medtronic products.
Laura is an interventional cardiologist who practiced at the Brigham and Women’s Hospital for 15 years. As an internationally renowned investigator and Professor of Medicine at Harvard Medical School, Laura helped shape clinical evaluation of new medical technology, providing a greater understanding of the interactions between medical devices, clinical practice, and concurrent pharmaceutical therapy. An expert in trial design, strategy and data analysis, she led numerous clinical trials to evaluate novel medical devices and pharmaceuticals, and held an array of major leadership positions, serving as the Chief Scientific Advisor for the Harvard Clinical Research Institute.
Laura received her A.B. from Harvard College and her M.D. from Harvard Medical School, both magna cum laude, and her M.Sc. (Clinical Epidemiology) from Harvard School of Public Health. She completed residency in internal medicine and fellowships in cardiovascular disease and interventional cardiology at the Brigham and Women’s Hospital.
Laura serves on the Board of directors of Medical Device Innovation Consortium (MDIC) and is a member of the NIH Advisory Committee. She is a member of the American Society of Clinical Investigation, the Association of University Cardiologists, a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and American College of Cardiology, and member of the Society of Cardiac Angiography and Intervention. She has authored approximately 200 original articles, served as a Senior Editor for the journal Circulation, and was awarded the Joseph A. Vita Award for Clinical Research by the American Heart Association in 2017.